Privi Speciality Chemicals Limited reported a solid performance for Q3 FY26, with consolidated revenue from operations at ₹6.05 billion and net profit at ₹779.9 million. The company also recorded strong nine-month growth and approved strategic equity infusion to support long-term expansion.
Privi Speciality Chemicals Limited announced its consolidated financial results for the quarter ended December 31, 2025, highlighting stable operational performance and healthy profitability amid evolving market conditions. The results were approved by the company’s Board of Directors as part of its Q3 FY26 earnings declaration.
Key Financial Performance Highlights
-
Consolidated revenue from operations stood at ₹6.05 billion during the December quarter, reflecting consistent demand across core speciality chemical segments.
-
Consolidated net profit for Q3 FY26 came in at ₹779.9 million, indicating effective cost management and operational efficiency.
-
Total income for the nine-month period ended December 31, 2025, increased to ₹18,572.26 million compared with ₹14,934.68 million in the corresponding period of the previous financial year.
-
Profit before tax for the nine-month period reached ₹3,100.20 million, showcasing a strong year-on-year improvement in overall earnings.
-
Earnings per share for the nine-month period were reported at ₹59.86 on a consolidated basis, while standalone earnings per share stood higher at ₹65.21.
Operational And Strategic Developments
-
The Board approved an equity infusion of ₹50 crore into its subsidiary, Prigiv Specialties Private Limited, while maintaining the existing joint venture shareholding structure.
-
-
The investment is aimed at strengthening the subsidiary’s operational capabilities and supporting future capacity expansion.
Statutory auditors conducted a limited review of the financial results and issued an unmodified conclusion, reaffirming compliance and financial transparency.
Sources: Company Regulatory Filings, InvestyWise, Stock Exchange Disclosures